Industry Overview

US silent attack market was valued at $1.8 billion in 2025 and is projected to reach $3.7 billion by 2035, growing at a CAGR of 7.2% from 2026 to 2035. Silent myocardial infarction, a form of cardiovascular disease with little to no noticeable symptoms, remains significantly underdiagnosed, increasing reliance on advanced diagnostic technologies for early detection. Key diagnostic tools include electrocardiogram (ECG) systems, cardiac biomarkers such as troponin tests, and advanced imaging solutions. The market comprises a wide range of products, including ECG devices, troponin-based diagnostic kits, cardiac imaging systems, wearable monitoring technologies, and interventional cardiology solutions. Market growth is primarily driven by the rising burden of cardiovascular diseases, an aging population, and the increasing prevalence of comorbid conditions such as diabetes and hypertension across the US.

Technological advancements continue to play a crucial role in enhancing diagnostic accuracy and early detection rates. In March 2026, iRhythm Technologies presented data at the ACC 2026 Annual Scientific Sessions, demonstrating that its Zio ambulatory ECG monitoring system detected a high prevalence of clinically actionable arrhythmias across diverse patient populations. These findings underscore the importance of long-term cardiac monitoring in identifying undiagnosed heart rhythm abnormalities, particularly among high-risk individuals. Additionally, in August 2025, GE HealthCare introduced the Vivid Pioneer, an AI-powered cardiovascular ultrasound system designed to improve imaging precision and workflow efficiency. Equipped with 2D, 4D, and AI-driven imaging capabilities, the system received both CE Mark and U.S. Food and Drug Administration 510(k) clearance, facilitating broader clinical adoption. These advancements are strengthening clinical decision-making and expanding early detection capabilities across hospitals and diagnostic centers.

Market Dynamics

AI Wearables Redefine Early Heart Attack Detection

Smart wearable and portable cardiac devices are transforming preventive healthcare across the United States by enabling continuous, real-time heart monitoring. These innovations allow early identification of irregular cardiac patterns, improving timely intervention. In January 2026, AliveCor received U.S. Food and Drug Administration clearance for enhanced cardiac determinations in its Kardia 12L ECG system. The upgraded AI-powered device can now detect up to 39 cardiac conditions with high precision. Its compact, handheld design supports easy and remote usage, increasing accessibility to advanced diagnostics. The technology is particularly effective in identifying conditions like myocardial infarction and ischemia. This advancement plays a key role in detecting asymptomatic cases such as silent heart attacks. As a result, it is significantly contributing to the growth of the U.S. silent heart attack diagnostics market.

Dual-Imaging Breakthrough Redefines Cardiac Precision

Interventional procedures such as angioplasty and stent placement play a critical role in managing silent heart attack cases. In October 2025, Terumo Interventional Systems received U.S. FDA 510(k) clearance for its OPUSWAVE dual sensor imaging system along with the DualView imaging catheter. This advanced system integrates optical frequency domain imaging (OFDI) and intravascular ultrasound (IVUS) into a single catheter platform. By combining these technologies, clinicians can obtain a more detailed and comprehensive visualization of coronary arteries. The innovation significantly improves procedural precision and diagnostic confidence during interventions. It also supports better assessment of arterial blockages and underlying coronary conditions. Overall, this development strengthens early detection and treatment capabilities, contributing to advancements in the U.S. silent heart attack diagnostic and interventional market.

Market Segmentation

• Based on diagnostic, the market is segmented into electrocardiogram (ECG), cardiac biomarker testing (troponin, CK-MB), cardiac imaging, and wearable & remote monitoring devices.
• Based on treatment type, the market is segmented into pharmacological treatment, interventional procedures, and lifestyle & preventive management.
• Based on end-user, the market is segmented into hospitals, cardiology clinics, diagnostic centers, and home care settings.

Next-Gen Diagnostics Transform Silent Heart Attack Detection

Advanced diagnostic technologies continue to lead the market, driven by their essential role in detecting asymptomatic cardiac events. High-sensitivity troponin assays and advanced imaging systems are increasingly adopted across hospitals and emergency care settings. In April 2025, Roche introduced a CE-marked Chest Pain Triage algorithm aimed at improving early detection of Acute Coronary Syndrome (ACS). The solution integrates high-sensitivity cardiac troponin testing to enable faster and more accurate clinical assessments. It helps healthcare professionals quickly rule in or rule out heart attacks, particularly in time-critical emergency scenarios. This advancement enhances diagnostic precision while reducing unnecessary hospital admissions. The innovation also supports more efficient clinical decision-making and patient management. Overall, such developments are strengthening the role of diagnostics in early cardiac event detection.

Market Players Outlook

The major companies operating in the U.S. silent heart attack market include Abbott Laboratories, Medtronic, Siemens Healthineers, Danaher, and Philips Healthcare, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their market presence and develop innovative diagnostic and treatment solutions.

Recent Development

• In February 2026, Medtronic announced its intent to acquire CathWorks to expand its cardiovascular diagnostics portfolio. The acquisition includes the AI-powered FFRangio system, a non-invasive technology used to assess coronary artery disease. This innovation enhances diagnostic capabilities by enabling more accurate and data-driven evaluation of heart conditions. The move strengthens advancements in early cardiac detection, supporting the broader U.S. silent heart attack diagnostics market.
• In January 2026, Medtronic announced CE Mark approval for its Affera Sphere-360 pulsed field ablation catheter and initiated first cases in a U.S. investigational device exemption (IDE) trial for treating atrial fibrillation. The device is designed for minimally invasive cardiac rhythm management using advanced ablation technology. While focused on treatment, such developments contribute to broader advancements in cardiovascular care.
• In November 2025, QuidelOrtho received 510(k) clearance from the S. Food and Drug Administration for its VITROS high-sensitivity Troponin I assay. The test enables precise measurement of cardiac troponin levels to aid in the diagnosis of myocardial infarction. This advancement supports faster and more accurate detection of heart attacks in clinical settings, enhancing early diagnosis capabilities.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Key companies operating in the US silent heart attack market
• Based on the availability of data, information related to new Protections and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.